https://novapharmanews.com/eu/news/ema-board-backs-ebola-response-flags-2025-annual-report-june-2026-meeting 2026-06-15T20:34:54.267Z NovaPharmaNews en 2026-06-15T20:34:54.309Z EMA board backs Ebola response, flags 2025 annual report at June meeting Ebola https://novapharmanews.com/uploads/articles/ema-board-backs-ebola-response-flags-2025-annual-report-june-2026-meeting.webp EMA board backs Ebola response, flags 2025 annual report at June meeting https://novapharmanews.com/us/news/medicare-price-rule-keytruda-opdivo-subcutaneous-launches 2026-06-15T20:09:22.171Z NovaPharmaNews en 2026-06-15T20:09:22.218Z Medicare price rule could hit Keytruda and Opdivo subcutaneous launches Keytruda, Opdivo, pembrolizumab, nivolumab, cancer https://novapharmanews.com/uploads/articles/medicare-price-rule-keytruda-opdivo-subcutaneous-launches.webp Medicare price rule could hit Keytruda and Opdivo subcutaneous launches https://novapharmanews.com/eu/news/ema-tightens-liver-safety-checks-tavneos-avacopan 2026-06-15T20:27:16.042Z NovaPharmaNews en 2026-06-15T16:37:18.363Z EMA Tightens Liver Safety Checks for Tavneos After Fatal Cases Tavneos, avacopan, vasculitis, ANCA-associated vasculitis, Anti-neutrophil Cytoplasmic Autoantibody-associated vasculitis https://novapharmanews.com/uploads/articles/ema-tightens-liver-safety-checks-tavneos-avacopan.webp EMA Tightens Liver Safety Checks for Tavneos After Fatal Cases https://novapharmanews.com/us/news/fda-approves-capivasertib-pten-deficient-prostate-cancer 2026-06-15T20:21:22.946Z NovaPharmaNews en 2026-06-15T16:08:06.911Z FDA Approves Capivasertib for PTEN-Deficient Prostate Cancer capivasertib, Truqap, abiraterone, prednisone, prostate cancer, PTEN-deficient prostate cancer, metastatic hormone-sensitive prostate cancer, metastatic androgen pathway modulation-naive prostate cancer https://novapharmanews.com/uploads/articles/fda-approves-capivasertib-pten-deficient-prostate-cancer.webp FDA Approves Capivasertib for PTEN-Deficient Prostate Cancer https://novapharmanews.com/us/news/fda-approves-belzutifan-plus-pembrolizumab-adjuvant-rcc 2026-06-15T19:57:12.105Z NovaPharmaNews en 2026-06-15T14:05:59.625Z FDA approves belzutifan plus pembrolizumab for adjuvant RCC belzutifan, Welireg, pembrolizumab, Keytruda, berahyaluronidase, renal cell carcinoma, advanced renal cell carcinoma, clear cell renal cell carcinoma https://novapharmanews.com/uploads/articles/fda-approves-belzutifan-plus-pembrolizumab-adjuvant-rcc.webp FDA approves belzutifan plus pembrolizumab for adjuvant RCC https://novapharmanews.com/apac/news/piyush-goyal-invites-global-pharma-firms-to-partner-with-india 2026-06-15T19:57:12.105Z NovaPharmaNews en 2026-06-15T12:02:53.384Z Piyush Goyal Invites Global Pharma Firms to Partner With India https://novapharmanews.com/uploads/articles/piyush-goyal-invites-global-pharma-firms-to-partner-with-india.webp Piyush Goyal Invites Global Pharma Firms to Partner With India https://novapharmanews.com/us/news/prescription-drug-freight-fraud-june-2026-report 2026-06-15T19:57:12.105Z NovaPharmaNews en 2026-06-15T10:10:51.698Z Prescription Drug Freight Fraud June 2026 report: what the record shows https://novapharmanews.com/uploads/articles/prescription-drug-freight-fraud-june-2026-report.webp Prescription Drug Freight Fraud June 2026 report: what the record shows https://novapharmanews.com/us/news/planning-a-successful-pivot-from-lab-to-clinic-practical-career-map 2026-06-15T19:57:12.105Z NovaPharmaNews en 2026-06-15T10:10:51.226Z Planning a successful pivot from lab to clinic: a practical career map https://novapharmanews.com/uploads/articles/planning-a-successful-pivot-from-lab-to-clinic-practical-career-map.webp Planning a successful pivot from lab to clinic: a practical career map https://novapharmanews.com/eu/news/fda-approves-capivasertib-abiraterone-prednisone-pten-deficient-mhspc 2026-06-15T21:05:46.851Z NovaPharmaNews en 2026-06-14T12:41:57.231Z FDA approves capivasertib plus abiraterone and prednisone in PTEN-deficient mHSPC capivasertib, Truqap, abiraterone, Zytiga, prednisone, prednisolone, abiraterone acetate, prostate cancer, metastatic androgen pathway modulation-naive prostate cancer, metastatic androgen pathway modulation-sensitive prostate cancer https://novapharmanews.com/uploads/articles/fda-approves-capivasertib-abiraterone-prednisone-pten-deficient-mhspc.webp FDA approves capivasertib plus abiraterone and prednisone in PTEN-deficient mHSPC https://novapharmanews.com/eu/news/china-big-pharma-essential-rd-partner 2026-06-15T19:57:12.105Z NovaPharmaNews en 2026-06-14T12:41:56.401Z China Becomes Big Pharma's Essential R&D Partner https://novapharmanews.com/uploads/articles/china-big-pharma-essential-rd-partner.webp China Becomes Big Pharma's Essential R&D Partner